Editas Medicine, Inc. - Common Stock (EDIT) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2016 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
EDIT on Nasdaq
Shares outstanding
82,773,190
Price per share
$2.05
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
43,072,975
Total reported value
$149,415,066
% of total 13F portfolios
0%
Share change
+1,741,103
Value change
+$7,922,393
Number of holders
190
Price from insider filings
$2.05
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Editas Medicine, Inc. - Common Stock (EDIT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 7.9% $10,527,922 6,539,082 BlackRock, Inc. 31 Mar 2025

As of 30 Sep 2025, 190 institutional investors reported holding 43,072,975 shares of Editas Medicine, Inc. - Common Stock (EDIT). This represents 52% of the company’s total 82,773,190 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Editas Medicine, Inc. - Common Stock (EDIT) together control 44% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 9.7% 8,019,891 +18% 0% $27,829,022
VANGUARD GROUP INC 8.4% 6,965,618 -2.7% 0% $24,170,694
Nuveen, LLC 2.5% 2,091,636 +120% 0% $7,257,977
GEODE CAPITAL MANAGEMENT, LLC 2.5% 2,040,166 +3.9% 0% $7,081,232
STATE STREET CORP 2.3% 1,925,044 +4.2% 0% $6,679,903
TWO SIGMA INVESTMENTS, LP 1.9% 1,584,155 +63% 0.01% $5,497,018
RENAISSANCE TECHNOLOGIES LLC 1.5% 1,277,400 +44% 0.01% $4,432,578
TWO SIGMA ADVISERS, LP 1.5% 1,205,000 +28% 0.01% $4,181,350
MORGAN STANLEY 1.3% 1,087,907 -23% 0% $3,775,037
BANK OF AMERICA CORP /DE/ 1.2% 1,024,240 -5.1% 0% $3,554,114
DIMENSIONAL FUND ADVISORS LP 1.1% 931,910 -34% 0% $3,233,961
JPMORGAN CHASE & CO 0.99% 820,667 -23% 0% $2,847,715
JACOBS LEVY EQUITY MANAGEMENT, INC 0.97% 800,023 +762% 0.01% $2,776,080
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.97% 799,210 -15% 0% $2,773,259
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.94% 779,955 +11% 0% $2,706,444
AQR CAPITAL MANAGEMENT LLC 0.83% 687,755 -10% 0% $2,386,510
NORTHERN TRUST CORP 0.81% 669,689 +1.4% 0% $2,323,821
STIFEL FINANCIAL CORP 0.7% 580,285 +4.5% 0% $2,013,592
KENNEDY CAPITAL MANAGEMENT LLC 0.68% 565,641 -0.35% 0.04% $1,962,774
JANE STREET GROUP, LLC 0.62% 516,595 +98% 0% $1,792,584
GOLDMAN SACHS GROUP INC 0.55% 458,276 -30% 0% $1,590,217
UBS Group AG 0.51% 422,394 -33% 0% $1,465,707
Walleye Capital LLC 0.48% 393,830 0.01% $1,366,590
CITADEL ADVISORS LLC 0.44% 362,193 -43% 0% $1,256,810
ROYAL BANK OF CANADA 0.43% 358,219 +16% 0% $1,243,000

Institutional Holders of Editas Medicine, Inc. - Common Stock (EDIT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 262,671 $542,430 +$31,866 $2.05 12
2025 Q3 43,072,975 $149,415,066 +$7,922,393 $3.47 190
2025 Q2 41,335,195 $90,959,890 -$2,651,384 $2.20 190
2025 Q1 44,017,732 $51,056,496 -$8,643,822 $1.16 189
2024 Q4 51,050,083 $64,829,211 -$26,980,305 $1.27 199
2024 Q3 55,026,910 $187,727,875 -$7,609,494 $3.41 223
2024 Q2 56,388,612 $263,332,828 -$55,730,958 $4.67 229
2024 Q1 67,934,083 $503,995,838 +$62,859,602 $7.42 221
2023 Q4 58,810,431 $595,736,469 -$24,830,057 $10.13 222
2023 Q3 61,671,930 $481,001,719 -$15,318,112 $7.80 220
2023 Q2 62,806,728 $516,820,804 +$83,105,555 $8.23 234
2023 Q1 52,966,709 $383,993,662 -$13,671,500 $7.25 231
2022 Q4 54,069,648 $479,580,650 +$43,275,611 $8.87 245
2022 Q3 48,268,099 $590,813,665 +$8,782,042 $12.24 243
2022 Q2 47,470,750 $561,353,937 +$5,825,446 $11.83 235
2022 Q1 45,377,308 $862,213,005 -$137,494,973 $19.02 239
2021 Q4 50,935,353 $1,354,989,098 -$58,058,784 $26.55 288
2021 Q3 51,686,909 $2,124,275,170 -$9,901,736 $41.08 307
2021 Q2 52,115,846 $2,960,972,143 -$42,349,447 $56.64 309
2021 Q1 53,112,966 $2,230,651,006 -$37,048,235 $42.00 296
2020 Q4 52,925,101 $3,710,809,621 -$146,422,850 $70.11 303
2020 Q3 55,153,663 $1,547,459,830 +$15,957,942 $28.06 233
2020 Q2 54,180,331 $1,601,145,803 +$263,790,568 $29.58 225
2020 Q1 45,615,983 $904,572,484 -$9,115,772 $19.83 186
2019 Q4 45,765,436 $1,355,110,145 +$25,771,039 $29.61 221
2019 Q3 44,998,047 $1,024,181,318 +$117,742,869 $22.74 180
2019 Q2 39,755,008 $983,423,600 +$65,857,366 $24.74 187
2019 Q1 37,451,919 $915,659,367 +$73,756,065 $24.45 194
2018 Q4 34,476,789 $784,057,800 +$24,196,841 $22.75 187
2018 Q3 33,225,759 $1,057,110,921 +$32,891,792 $31.82 192
2018 Q2 32,137,091 $1,150,684,888 +$38,224,646 $35.83 208
2018 Q1 31,152,906 $1,032,691,989 +$25,997,611 $33.15 192
2017 Q4 30,385,119 $934,032,943 +$80,818,257 $30.73 146
2017 Q3 27,385,418 $657,479,359 +$43,906,788 $24.01 115
2017 Q2 25,837,623 $433,614,752 +$21,311,417 $16.78 107
2017 Q1 27,537,538 $614,414,843 +$120,573,551 $22.32 99
2016 Q4 23,494,260 $381,310,290 +$21,340,854 $16.23 84
2016 Q3 22,215,862 $299,468,288 +$9,006,129 $13.48 71
2016 Q2 17,634,311 $429,193,163 -$15,061,641 $24.40 64
2016 Q1 18,151,358 $625,254,000 +$464,066,000 $34.54 48